## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

See Instruction 10.

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Koo Jakap</u>							2. Issuer Name and Ticker or Trading Symbol Apimeds Pharmaceuticals US, Inc. [ APUS ]									ationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner			
(Last) 2 EAST I		3. Date of Earliest Transaction (Month/Day/Year) 05/16/2025									Office below	r (give title )		Other (s below)	specify				
2ND FLO (Street) HOPEW1	ELL N	J tate)	4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (CheckApplicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tabi	e I - No	n-Deriv	/ative	Sec	curitie	s Ac	quired, E	)isp	osed o	of, or Be	neficia	llv (	Owne	d			
1. Title of Security (Instr. 3) 2. Tra					action Day/Year)	2A Ex	A Deeme kecution any lonth/Da	d Date,	3. Transacti Code (In	on	4. Securities Acquired (A Disposed Of (D) (Instr. 3 and 5)			A) or 5. Am 3, 4 Secu Bene Owne		int of es ially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v		Amount (A) or (D)			Reported Transaction(s) (Instr. 3 and 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A Deemed Execution Date, if any (Month/Day/Year)		4. Transact Code (Instr. 8)		5. Number of Deriva Securi Acquir (A) or Dispos of (D) (Instr. and 5)	tive ties ed sed	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an Amount o Securities Underlyin Derivative Security ( and 4)	f s ng	of Dei Sec	Price rivative curity str. 5)	derivative tive Securities ty Beneficial	e O s Fe illy D o g (l)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Ex Da	piration te	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$1.73	05/16/2025			A		5,780		(1)	05/	/16/2035	Common Stock, par value \$0.01 per share	5,780		\$0	5,780		D	

## Explanation of Responses:

1. The option will vest in full and become exercisable on 05/16/2026.

/s/ Nelson Mullins Riley &

Scarborough LLP, Attorney-in- 05/20/2025

<u>Fact</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).